Table 3 |
||||||||||||||||||||
|
GFR and proteinuria stages, and CKD prevalence by different equations according to 2009 KDIGO classification |
||||||||||||||||||||
|
G1 |
G2 |
G3a |
G3b |
G4 |
G5 |
CKD ALL |
CKD 3-5 |
|||||||||||||
|
|
||||||||||||||||||||
|
CKD-EPI |
27.5 |
60.4 |
9.2 |
2.3 |
0.6 |
0.1 |
19.7a |
12.1a |
||||||||||||
|
25.5 |
1.8 |
0.2 |
54.8 |
5.1 |
0.5 |
7.6 |
1.5 |
0.1 |
1.7 |
0.5 |
0.1 |
0.5 |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|||
|
|
||||||||||||||||||||
|
S-MDRD |
11.2 |
67.5 |
16.8 |
2.7 |
0.6 |
0.1 |
27.1a |
20.2a |
||||||||||||
|
11.1 |
1.0 |
0.1 |
61.8 |
5.2 |
0.5 |
14.6 |
2.0 |
0.2 |
2.0 |
0.6 |
0.1 |
0.5 |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|||
|
|
||||||||||||||||||||
|
J-EPI |
3.2 |
58.9 |
30.7 |
5.8 |
1.3 |
0.1 |
43.0a |
37.9a |
||||||||||||
|
2.9 |
0.2 |
0.1 |
54.1 |
4.4 |
0.4 |
27.4 |
3.0 |
0.3 |
4.7 |
1.0 |
0.1 |
1.0 |
0.2 |
0.1 |
0.1 |
0.0 |
0.0 |
|||
|
|
||||||||||||||||||||
|
C-MDRD |
45.6 |
48.9 |
4.0 |
1.3 |
0.2 |
0.05 |
14.2b |
5.5b |
||||||||||||
|
41.7 |
3.5 |
0.4 |
44.1 |
4.4 |
0.4 |
3.1 |
0.8 |
0.1 |
1.0 |
0.2 |
0.1 |
0.2 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|||
|
|
||||||||||||||||||||
|
T-GFR |
29.2 |
65.5 |
4.3 |
1.1 |
0.1 |
0.04 |
14.0 |
5.4 |
||||||||||||
|
27.1 |
1.8 |
0.3 |
58.9 |
6.0 |
0.6 |
3.2 |
1.0 |
0.1 |
0.9 |
0.2 |
0.0 |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|||
|
|
||||||||||||||||||||
|
Data shown as percentages of all subjects (n-5526) for each GFR stage (G1-5) and for each proteinuria subdivision (represented as 3 subdivisions of each G stage from A1 to A2 to A3 from left to right). CKDALL CKD from stage 1 to 5, CKD3-5 CKD stages 3 to 5 a CKD prevalence different compared to all other equations (p < 0.001) b CKD prevalence different to other equations (p < 0.001) except with T-GFR CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; S-MDRD, standard MDRD; C-MDRD, Chinese MDRD; J-EPI, Japanese CKD-EPI; T-GFR, Thai GFR |
||||||||||||||||||||
|
Kitiyakara et al. BMC Nephrology 2012 13:1 doi:10.1186/1471-2369-13-1 |
||||||||||||||||||||
